Extended indication Breyanzi voor de behandeling van recidief of refractair grootcellig B-cellymfoom (R/R DLBCL), primai
Therapeutic value Possible added value
Total cost 73,024,248.00
Registration phase Registered and reimbursed

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information